NextCell Pharma AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXTCL.ST research report →
Companywww.nextcellpharma.com
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.
- CEO
- Mathias Svahn
- IPO
- 2017
- Employees
- 24
- HQ
- Huddinge, SE
Price Chart
Valuation
- Market Cap
- $125.65M
- P/E
- -3.07
- P/S
- 12.72
- P/B
- 2.48
- EV/EBITDA
- -2.58
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -222.84%
- Op Margin
- -423.10%
- Net Margin
- -413.93%
- ROE
- -78.09%
- ROIC
- -74.78%
Growth & Income
- Revenue
- $10.94M · 2.56%
- Net Income
- $-35,143,091 · 16.25%
- EPS
- $-0.46 · 19.30%
- Op Income
- $-35,871,789
- FCF YoY
- -13.69%
Performance & Tape
- 52W High
- $1.78
- 52W Low
- $0.63
- 50D MA
- $1.22
- 200D MA
- $1.07
- Beta
- 0.65
- Avg Volume
- 488.21K
Get TickerSpark's AI analysis on NXTCL.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NXTCL.ST Coverage
We haven't published any research on NXTCL.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NXTCL.ST Report →